JONATHAN C MAN
Broker in Cambridge, MA
License number
Massachusetts 9085435
Issued Date
Jan 18, 2006
Expiration Date
Feb 16, 2008
Type
Salesperson
Address
Address
Cambridge, MA 02139
Professional information
Formulations Decreasing Particle Exhalation
US Patent:
8187637, May 29, 2012
Filed:
Mar 6, 2007
Appl. No.:
11/714999
Inventors:
David A. Edwards - Boston MA, US
Jonathan C. Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Canton MA, US
Jonathan C. Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Canton MA, US
Assignee:
Pulmatrix, Inc. - Lexington MA
International Classification:
A61K 9/00, A61K 9/08, A61K 9/10, A61K 9/12, A61K 9/14
US Classification:
424489, 424 46
Abstract:
Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
Formulations Decreasing Particle Exhalation
US Patent:
8591866, Nov 26, 2013
Filed:
Apr 25, 2012
Appl. No.:
13/455585
Inventors:
David A. Edwards - Boston MA, US
Jonathan Chun-Wah Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Medfield MA, US
Jonathan Chun-Wah Man - Cambridge MA, US
Jeffrey P. Katstra - Watertown MA, US
Robert W. Clarke - Medfield MA, US
Assignee:
Pulmatrix, Inc. - Lexington MA
International Classification:
A61K 9/00, A61K 9/12, A61K 9/14
US Classification:
424 46, 424489
Abstract:
Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
Formulations Decreasing Particle Exhalation
US Patent:
2005020, Sep 22, 2005
Filed:
Nov 17, 2004
Appl. No.:
10/990996
Inventors:
David Edwards - Boston MA, US
Jonathan Man - Cambridge MA, US
Jeffrey Katstra - Watertown MA, US
Robert Clarke - Canton MA, US
Jonathan Man - Cambridge MA, US
Jeffrey Katstra - Watertown MA, US
Robert Clarke - Canton MA, US
International Classification:
A61L009/04, A61K048/00, A61K038/17, A61K031/70, A61K031/715
US Classification:
424044000, 514002000, 514044000, 514054000, 514561000
Abstract:
Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.